^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    PDE4 inhibitor

    Related drugs:
    20h
    The Safety and Efficacy of Roflumilast Foam in HS (clinicaltrials.gov)
    P2, N=20, Recruiting, Beth Israel Deaconess Medical Center | Not yet recruiting --> Recruiting
    Enrollment open
    7d
    MN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and Hypertriglyceridemia (clinicaltrials.gov)
    P2, N=40, Active, not recruiting, MediciNova | Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2025 --> Dec 2026
    Enrollment closed • Trial primary completion date
    9d
    Apremilast for Alcohol Use Disorder Treatment in Women and Men (clinicaltrials.gov)
    P1, N=10, Active, not recruiting, Yale University | Trial completion date: Feb 2026 --> Aug 2026 | Trial primary completion date: Feb 2026 --> Aug 2026
    Trial completion date • Trial primary completion date
    10d
    Dose-response Study of Apremilast in Women and Men With Alcohol Use Disorder (clinicaltrials.gov)
    P2, N=120, Not yet recruiting, Yale University | Initiation date: Nov 2025 --> Mar 2026
    Trial initiation date
    12d
    A phase II clinical Trial on the efficacy and safety of TQC3721 inhalation powder (ChiCTR2500112449)
    P2, N=195, Not yet recruiting, West China Hospital, Sichuan University; Chia Tai Tianqing Pharmaceutical Group Co., Ltd
    New P2 trial
    17d
    Evaluation the Topical Apremilast Nanoformulation in Treatment of Localized Plaque Psoriasis (clinicaltrials.gov)
    P=N/A, N=36, Not yet recruiting, Assiut University
    New trial
    17d
    Comparative Study of Crisaborole vs. Tacrolimus in Atopic Dermatitis (clinicaltrials.gov)
    P4, N=30, Not yet recruiting, Cairo University
    New P4 trial
    22d
    Diuretic Effect of Aminophylline and Furosemide in Adult Patients Undergoing Cardiac Surgical Procedures (clinicaltrials.gov)
    P=N/A, N=106, Recruiting, Cairo University | Not yet recruiting --> Recruiting
    Enrollment open
    24d
    Ulcerative pyoderma gangrenosum in a 78-year-old woman treated with brodalumab: A case report. (PubMed, SAGE Open Med Case Rep)
    The patient was refractory to corticosteroids, dapsone, and roflumilast, and developed recurrent Gram-negative infections. Brodalumab may offer a safe and effective treatment option in refractory pyoderma gangrenosum, particularly in patients with contraindications to conventional therapies. This case supports further evaluation of IL-17 pathway inhibition in neutrophilic dermatoses.
    Journal
    |
    IL17A (Interleukin 17A) • IL17RA (Interleukin 17 Receptor A)
    |
    roflumilast
    27d
    Diuretic Effect of Aminophylline and Furosemide in Adult Patients Undergoing Cardiac Surgical Procedures (clinicaltrials.gov)
    P=N/A, N=106, Not yet recruiting, Cairo University
    New trial
    29d
    Maximal Usage Pharmacokinetics and Safety Study of ARQ-154 Foam 0.3% in Pediatric Participants With Scalp and Body Psoriasis (clinicaltrials.gov)
    P1, N=16, Recruiting, Arcutis Biotherapeutics, Inc.
    New P1 trial